A Comprehensive Review of Targeted Therapy in Cancer Treatment

Targeted therapy has reshaped oncology by focusing on molecular abnormalities that drive cancer growth. Unlike conventional chemotherapy, which attacks dividing cells broadly, these agents interfere with specific pathways. This analysis examines recent shifts in the field, the underlying science, patient considerations, expected outcomes, and areas to monitor.

Recent Trends

Over the past few years, the range of approved targeted agents has expanded beyond kinase inhibitors to include antibody-drug conjugates, bispecific antibodies, and small molecules that exploit synthetic lethality. Liquid biopsy adoption has increased, allowing non-invasive detection of resistance mutations. Combination approaches—pairing targeted therapy with immunotherapy or hormone therapy—are becoming more common in clinical practice, especially for tumors with multiple driver alterations.

• Rise of next-generation sequencing panels enabling simultaneous analysis of dozens of cancer genes.
• Growing use of targeted agents earlier in treatment lines, including adjuvant settings.
• Development of agents that target previously undruggable proteins (e.g., KRAS G12C inhibitors).

Background

Targeted therapy stems from the discovery that many cancers harbor somatic mutations in genes responsible for cell growth, survival, and angiogenesis. First-generation agents such as imatinib for BCR-ABL–positive chronic myeloid leukemia demonstrated that matching a drug to a specific genetic alteration could yield durable responses. Since then, the field has matured to include inhibitors of EGFR, ALK, BRAF, HER2, and others. Resistance mechanisms have also been characterized, leading to successive generations of drugs that overcome common escape pathways.

User Concerns

Patients and clinicians face several practical questions when considering targeted therapy:

• Which patients qualify? Eligibility depends on identifying a specific biomarker through tumor or blood testing—not all individuals with a given cancer type will harbor the matching alteration.
• How durable are responses? While some patients experience prolonged disease control, resistance often develops within months to a few years, and strategies to delay or manage resistance are still being refined.
• What about side effects? Targeted drugs cause toxicities distinct from chemotherapy—such as rash, diarrhea, hypertension, or pneumonitis—that require proactive monitoring and dose adjustments.
• Are costs covered? Insurance policies vary widely, and access may depend on institutional formularies or manufacturer assistance programs, which can change over time.
• How do patients handle progression? After failure of one targeted agent, the next step may involve repeat biopsy or liquid biopsy to identify emergent resistance mutations, guiding selection of a subsequent line of therapy.

Likely Impact

Ongoing advances are expected to shift treatment paradigms in several ways. For patients with actionable mutations, targeted therapy can offer improved response rates and sometimes better quality of life compared to chemotherapy. However, long-term survivorship data remain limited for many newer agents. The growing complexity of treatment algorithms may increase the burden on both physicians and patients to keep up with evolving biomarker interpretation and sequencing options. At a population level, broader genomic testing could improve equity in access to effective therapies, though disparities in test availability and reimbursement continue to exist.

• Increased reliance on real-world evidence and registry studies to fill gaps left by clinical trials.
• Potential for expanded approvals in tumor-agnostic indications for drugs that target rare, shared mutations.
• Integration of targeted therapy into multi-modal care plans alongside surgery, radiation, and systemic treatments.

What to Watch Next

Several developments will shape the next phase of targeted therapy:

• Next-generation proteolysis-targeting chimeras (PROTACs) and molecular glues that degrade rather than inhibit proteins.
• Broader adoption of combination strategies to prevent or overcome resistance, particularly with agents targeting parallel signaling pathways.
• Refinement of non-invasive monitoring tools (e.g., circulating tumor DNA assays) to detect minimal residual disease and guide early intervention.
• Regulatory decisions on expanding biomarker testing requirements and on drugs that target mutations with very low prevalence.
• Long-term safety data from post-marketing studies, especially for newer antibody-drug conjugates that carry risk of ocular and pulmonary toxicities.